Prevention of catheter-related bladder discomfort – pudendal nerve block with ropivacaine versus intravenous tramadol: study protocol for a randomized controlled trial

Jing-yi Li and Ren Liao

Abstract

Background: Catheter-related bladder discomfort (CRBD) is a common distressing symptom complex during the postoperative period, especially after urologic procedures with a relatively greater size urinary catheter. In this study, we will enroll male patients undergoing elective prostate surgery with urinary catheterization under general anesthesia, and we will compare the efficacy of pudendal nerve block (PNB) and intravenous tramadol in CRBD prevention.

Methods/design: This trial is a prospective, randomized controlled trial that will test the superiority of bilateral PNB with 0.33 % ropivacaine compared with intravenous tramadol 1.5 mg/kg for CRBD prevention. A total of 94 male patients undergoing elective prostate surgery with urinary catheterization after anesthesia induction will be randomized to receive either bilateral PNB with 0.33 % ropivacaine (the PNB group) or intravenous tramadol 1.5 mg/kg (the tramadol group) after the completion of surgery. The primary outcome is the incidence of CRBD. The most important secondary outcome is the severity of postoperative CRBD, and other secondary outcomes include Numeric Rating Scale (NRS) score for postoperative pain; incidence of postoperative side effects such as postoperative nausea/vomiting, sedation, dizziness, and dry mouth; postoperative requirement for tramadol as a rescue treatment for CRBD and sufentanil as a rescue analgesic for postoperative pain; and NRS score for acceptance of an indwelling urinary catheter.

Discussion: This trial is planned to test the superiority of PNB with 0.33 % ropivacaine compared with intravenous tramadol 1.5 mg/kg. It may provide a basis for a new clinical practice for the prevention of CRBD.

Trial registration: ClinicalTrials.gov identifier NCT02683070. Registered on 11 February 2016.

Keywords: Catheter-related bladder discomfort, Pudendal nerve block, Tramadol, Randomized controlled trial

Abbreviations: CONSORT, Consolidated Standards of Reporting Trials; CRBD, Catheter-related bladder discomfort; PNB, Pudendal nerve block; NRS, Numeric Rating Scale; PACU, Postanesthesia care unit; SPIRIT, Standard Protocol Items: Recommendations for Interventional Trials
**Background**

Catheter-related bladder discomfort (CRBD) in patients with urinary catheterization during operation is frequently reported in the postanesthesia care unit (PACU) [1]. It is a distressing symptom complex characterized as a burning sensation or stabbing pain with an urge to void or as discomfort from the suprapubic area to the urethra [2]. The condition of CRBD may aggravate postoperative pain, increase the incidence of postoperative complications, and result in prolongation of hospital stay [2–4].

The mechanism of CRBD is mediated by type 3 muscarinic receptor activation, which increases acetylcholine release and then causes the detrusor muscles of the bladder to contract involuntarily [5]. Antimuscarinic agents, including tramadol, tolterodine, oxybutynin, pregabalin, and ketamine, have been applied to treat CRBD in clinical practice [6–10]. However, in spite of their beneficial effect on CRBD, systemic administration of these agents is associated with side effects such as nausea or vomiting, sedation, dizziness, or other unpleasant complications, which may result in reduced quality of recovery. It is important in clinical practice to establish an effective treatment for CRBD with reduced adverse effects.

Anatomically, the afferent nerves of the urethra and bladder triangle are derived from sacral somatic nerves (S2–S4 segment) [5] and theoretically, prevention of CRBD should be achieved by blocking these nerves. The pudendal nerve, the main nerve of the perineum, is derived from the ventral rami of the second, third, and fourth sacral spinal nerves; innervates the urethral sphincter and muscles of the perineum and pelvic floor; and provides sensation to the penis in males and the clitoris in females, as well as to the urethra and bladder triangle [11, 12]. Clinically, pudendal nerve block (PNB) has been applied for analgesia of labor and/or vaginal birth [13], vaginal repair [14], sphincterotomy [15], and treatment of pudendal neuralgia [16], and the safety and effectiveness of PNB have been identified [12–16]. On the basis of the anatomical and physiological proof for nerve innervation, with the support of clinical experience, we designed this trial with the hypothesis that PNB has a CRBD-reductive effect with less side effects related to systemic administration of antimuscarinic agents than PNB with ropivacaine and intravenous tramadol, and we aim to provide a novel and effective way to reduce the incidence of CRBD and with a better outcome.

**Methods/design**

**Design**

The PNB trial (ClinicalTrials.gov identifier NCT02683070) is an investigator-initiated, prospective, randomized controlled trial that will test the superiority of PNB with 0.33 % ropivacaine to intravenous tramadol 1.5 mg/kg for reduction of CRBD. It will be conducted in accordance with the principles outlined in the Declaration of Helsinki and will follow the Consolidated Standards of Reporting Trials (CONSORT) statement (http://www.consort-statement.org/). A brief flow diagram of the PNB trial is provided in Fig. 1, and a populated Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist is provided in Additional file 1.

The study has no external financial sponsor, and there are no conflicts of interest in the study design, data collection, analysis, or results interpretation. Before we start the study, all of the participants, including physicians, interns, and nurses, will be educated and trained, and some of them will be responsible for follow-up. After the completion of this trial, the role of the participants, including trial designer, trial executor, and staff responsible for follow-up, will be stated in detail.

**Sample size calculation**

The incidence of CRBD has been reported to range from 47 % to 90 % according to different types of surgery, and male sex has been identified to be an independent predictor in previous studies [1, 3]. We investigated 367 male patients in the PACU of the Department of Anesthesiology, West China Hospital, from 21 June 21 to 17 July 2015 and found that 56.1 % (206 of 367) of them complained of CRBD. On the basis of this information, a difference of 25 % (e.g., 30 % vs. 55 %) in the incidence of CRBD values between two treatment groups is considered to be clinically important. The sample size was calculated...
to compare two proportions with two-sample noninferiority or superiority; assuming the difference between two groups at a 5% significance level and a power of 0.80, 37 patients in each group are required for a comparison within the groups. Considering an estimated 20% dropout rate, 47 patients in each group, and 94 patients in total, are required in this study.

Recruitment

A total of 94 patients undergoing elective prostate surgery in lithotomy position with urinary catheterization (16-French Foley catheter) while under general anesthesia will be enrolled at West China Hospital of Sichuan University.

Randomization and blinding

A biostatistician in the Department of Anesthesiology, West China Hospital of Sichuan University, will perform randomization using SAS version 9.1 software (SAS Institute, Cary, NC, USA). For the purpose of blinding, the results of randomization and group allocation will be concealed in a nontransparent envelope and kept by a research assistant. After confirmation of the patient’s enrollment, the investigator will call the research assistant to get the allocated group and intervention by opening the envelope. The investigators, research assistant, and responsible physicians will not be blinded to the treatment assignment, and the patients, staff responsible for follow-up, and statisticians will be blinded to it.

Study organization

The study will be supervised for data completeness and accuracy by the Department of Anesthesiology, West China Hospital, and RL will be responsible for data monitoring and alerting for serious complications. The data safety and monitoring board will be involved for the duration of the trial. There are no stop rules in this pilot study, and no preliminary analysis will be performed before the completion of this study.

Enrollment criteria

The following are the inclusion criteria:

- Male patients aged 18–80 years
- Undergoing elective prostate surgery in lithotomy position with urinary catheterization while under general anesthesia

The exclusion criteria are as follows:

- History of bladder dysfunction, including overactive bladder, which is defined as urinary frequency more than three times in the night or more than eight times in 24 h [5]; neurogenic bladder; and bladder outflow obstruction
- Coagulation disorders
- History of vestibular dysfunction
- History of substance abuse
- Known allergy to ropivacaine, tramadol, or any other anesthetic agent
- History of postoperative delirium
- Impairment of cognitive function

Interventions

In the PNB group, bilateral PNB with 30 ml of 0.33% ropivacaine (15 ml for each side) will be performed after the operation is finished. In the tramadol group, intravenous tramadol 1.5 mg/kg will be administered after the operation is finished.

Outcome measures

All patients will be extubated after completion of the operation and then transferred to the PACU for outcome evaluation. Patients will be asked directly and observed by staff responsible for follow-up who were blinded to the group assignments for outcomes at 0, 0.5, 1, 2, 4, and 6 h after patient arrival in the PACU and after extraction of the urinary catheter. A questionnaire designed to collect the outcome data is shown in Table 1.

Primary outcome

The primary outcome is the incidence of postoperative CRBD.

Secondary outcomes

The following are the secondary outcomes of interest in the trial:

1. The most important secondary outcome is the severity of postoperative CRBD, which will be assessed with a 4-point scale as follows: 0 = no CRBD; 1 = mild CRBD, existing only upon asking about it; 2 = moderate CRBD, stated by the patient spontaneously; and 3 = severe CRBD, demonstrated by behavioral response such as strong vocal responses or attempting to pull out the catheter [2]. When the severity of CRBD is evaluated as 2 or 3, the patient will be administered intravenous tramadol 1.5 mg/kg as a rescue treatment for bladder discomfort reduction [6], and postoperative tramadol requirement will be recorded and compared.

2. Postoperative pain will be evaluated by the patients themselves using a single 11-point Numeric Rating Scale (NRS), which ranges from 0 to 10, where 0 indicates “no pain” and 10 represents “worst imaginable pain” [17]. If the patient complains about pain with an NRS score greater than 4, intravenous sufentanil 5 μg will be administered as a rescue analgesic treatment, and postoperative sufentanil requirement will be recorded and compared.
Table 1 Questionnaire for pudendal nerve block trial outcome evaluation

1. Do you feel any discomfort in your suprapubic area or urethra?
   □ No → jump to the third question. → scoring 0.
   □ Yes

2. What’s the degree of your discomfort?
   □ Mild, existing only on asking about it. (Patient doesn’t state the discomfort spontaneously) → scoring 1.
   □ I feel discomfort even you don’t ask me about it. (Patient states the discomfort spontaneously) → scoring 2.
   □ I feel very discomfort, some feeling like I’m in urge to void, burning sensation in my urethra. (Patient not only states the discomfort spontaneously, but also with painful expression, or behavioral response such as strong vocal responses or attempting to pull out the catheter) → scoring 3.

   * Give patient intravenous tramadol 1.5mg/kg when scoring 2 or 3.

   The total dose of tramadol is (     )mg.

3. Do you feel any pain? Imaging 0 represents “no pain” and 10 represents “worst imaginable pain”, please sign the number in this figure.

   ![Pain Scale](image)

   * If the patient complains about pain score greater than 4, give patient intravenous sufentanil 5 μg.

   The total dose of sufentanil is (     ) μg.

4. Do you feel nausea?
   □ No.
   □ Yes → Give patient intravenous ondansetron 4mg.

   * If the patient is observed vomiting, give patient intravenous ondansetron 4mg again.

   The total dose of ondansetron is (     )mg.

5. Is this patient sedated? Please score his state of sedation with Ramsay sedation scale.
   □ 1: anxious, agitated or restless.
   □ 2: co-operative, oriented, and tranquil.
   □ 3: responds to command; asleep.
   □ 4: brisk response to light glabellar tap or loud noise.
   □ 5: sluggish response to light glabellar tap or loud noise.
   □ 6: no response.

6. Do you feel dizziness?
   □ No.
   □ Yes.

7. Do you feel dry mouth?
   □ No.
   □ Yes.
3. Postoperative side effects will be recorded and analyzed. These include postoperative nausea/vomiting, sedation, dizziness, and dry mouth. Sedation will be assessed using the Ramsay Sedation Scale (1 = anxious, agitated, or restless; 2 = cooperative, oriented, and tranquil; 3 = responds to command, asleep; 4 = brisk response to light glabellar tap or loud noise; 5 = a sluggish response to light glabellar tap or loud noise; and 6 = no response) [18]. Patients with a Ramsay Sedation Scale score greater than 4 will be considered sedated.

4. Acceptance of the indwelling urinary catheter will be evaluated by using an NRS score ranging from 0 (totally not acceptable) to 10 (totally acceptable) after extraction of the catheter.

5. The incidence of complications related to PNB, including hemorrhage and/or hematoma, infection of injection site, and accidental systemic administration of ropivacaine, which will be recorded and evaluated for overall safety of this technique, will be recorded.

Statistical analysis
An intention-to-treat analysis will be performed to compare all primary and secondary outcomes with the use of SPSS version 18.0 software (SPSS, Inc., Chicago, IL, USA). Demographic data will be compared using Student’s t test. The incidence of CRBD and postoperative side effects will be analyzed by chi-square test. The severity of CRBD will be analyzed using Fisher’s exact test. NRS scores for postoperative pain and acceptance of the indwelling urinary catheter will be analyzed using the Mann-Whitney U test. Postoperative tramadol and sufentanil requirements will be analyzed using the Z test. \( p < 0.05 \) will be considered to be statistically significant.

Discussion
PNB, a local anesthetic technique, has been applied widely in patients undergoing perineal and vaginal surgery [13–15], for relief of pudendal neuralgia [16], and for treatment of detrusor-sphincter dyssynergia and external urethral sphincter hypertonicity in patients with spinal cord injury [19, 20]. In addition, a combination of pudendal and periprostatic nerve block has been reported to improve pain reduction during transperineal prostate biopsy compared with periprostatic anesthesia only [21].

There are several limitations of this trial. First, with regard to the study design, because of different routes of administration (nerve block vs. intravenous), the investigator and responsible physicians will not be blind to group allocation. Second, PNB will be performed with the patient in lithotomy position in current clinical practice, so we will choose patients undergoing prostate surgery placed in the lithotomy position. Therefore, a limitation exists in the application of PNB to patients undergoing other operations in the supine, prone, or other position, and other routes of PNB should be explored in the next step. Third, for patients undergoing medical procedures requiring urinary catheterization without any surgical intervention, the risks and benefits of PNB should be balanced, and this aspect will not be discussed in this study. In addition, CRBD is a very subjective feeling, and it can be defined only semiquantitatively on the basis of the patient’s own complaint and hand.
the physician’s judgment. That is why the incidence of CRBD varies in different articles [1, 3], and we will try our best to get an accurate measurement of CRBD by careful follow-up.

In summary, this trial is designed to find an optimal clinical practice for CRBD reduction by performing a superiority test for the PNB with 0.33 % ropivacaine compared with intravenous tramadol 1.5 mg/kg.

**Trial status**
The study is not yet recruiting as of the date of publication.

**Additional file**

Additional file 1: Standard Protocol Items: Recommendations for Interventions Trials (SPIRIT) 2013 checklist: recommended items to address in a clinical trial protocol and related documents. (DOC 117 kb)

**Acknowledgements**

No funding was received from any sponsors related to this trial. The authors extend special thanks to all participants in this study.

**Authors’ contributions**
JL and RL collaborated to design the study protocol. JL will be the principal investigator responsible for trial design, patient recruitment, and coordination with other staff to carry out the trial. Both authors read and approved the final manuscript.

**Competing interests**
The authors declare that they have no competing interests.

**Ethics approval and consent to participate**
The PNB trial was approved on 22 February 2016 by the Biological-Medical Ethics Committee of West China Hospital, Sichuan University, with the registration number 2015-306. Details of the trial will be introduced by the investigators to all potential participants at the preoperative interview, and the signed informed consent form must be provided by all eligible participants prior to enrollment.

**Author details**
1. Department of Dermatovenereology, West China Hospital, Sichuan University, Chengdu 610041, People’s Republic of China.
2. Department of Anesthesiology, West China Hospital of Sichuan University, 37 Guoxue Lane, Chengdu 610041, Sichuan Province, People’s Republic of China.

**Received:** 23 March 2016 **Accepted:** 25 August 2016

**Published online:** 13 September 2016

**References**
1. Binhas M, Motamed C, Hawajri N, Yiou R, Marty J. Predictors of catheter-related bladder discomfort in the post-anesthesia care unit. Ann Fr Anesth Reanim. 2011;30(2):122–5.
2. Wilson M. Causes and management of indwelling urinary catheter-related pain. Br J Nurs. 2008;17(4):232–9.
3. Bai Y, Wang X, Li X, Pu C, Yuan H, Tang Y, et al. Management of catheter-related bladder discomfort in patients who underwent elective surgery. J Endourol. 2015;29(6):640–9.
4. Lepouse C, Lautner CA, Liu L, Gomis P, Leon A. Emergence delirium in adults in the post-anesthesia care unit. Br J Anaesth. 2006;96(6):747–53.
5. Andersson KE, Wein AJ. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev. 2004; 56(4):581–631.
6. Agarwal A, Yadav G, Gupta D, Singh PK, Singh U. Evaluation of intraoperative tramadol for prevention of catheter-related bladder discomfort: a prospective, randomized, double-blind study. Br J Anaesth. 2008;101(4):506–10.
7. Agarwal A, Raza M, Singh V, Dhinaia S, Kapoor R, Srivastava A, et al. Evaluation of efficacy of tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled double blind study. Anesth Analg. 2005;101(4):1065–7.
8. Agarwal A, Dhinaia S, Singh V, Kapoor R, Tandon M. Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study. Br J Anaesth. 2006;96(3):377–80.
9. Srivastava VK, Agrawal S, Kadiyala VN, Ahmed M, Sharma S, Kumar R. The efficacy of pregabalin for prevention of catheter-related bladder discomfort: a prospective, randomized, placebo-controlled double-blind study. J Anesth. 2015;29(2):212–6.
10. Shariat Moharari R, Lajevardi M, Rajavi M, Najafi A, Shariat Moharari J, Etozadi F. Effects of intra-operative ketamine administration on postoperative catheter-related bladder discomfort: a double-blind clinical trial. Pain Pract. 2014;14(2):146–50.
11. Agar AMR, Daley 2nd AF. Grant’s atlas of anatomy. 13th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2013. ISBN 978-1-60831-256-1.
12. Shafik A, el-Sherif M, Youssef A, Olfat ES. Surgical anatomy of the pudendal nerve and its clinical implications. Clin Anat. 1995;8(2):110–5.
13. Anderson D. Pudendal nerve block for vaginal birth. J Midwifery Womens Health. 2014;59(6):651–9.
14. Rouholaamin S, Jabalameli M, Abdi M. The effect of preemptive pudendal nerve block on pain after anterior and posterior vaginal repair. Adv Biomed Res. 2015;4:153.
15. Alkhaidi HM, Salaita WM, Shabanah MA, AH-Horat MI, Aladbabsa MM, Uruiqat AA. Postoperative outcome comparison between pudendal nerve block and caudal block after lateral open internal sphincterotomy. Med Arch. 2015; 69(3):187–9.
16. Ricci P, Wash A. Pudendal nerve block by transgluteal way guided by computed tomography in a woman with refractory pudendal neuralgia expressed like chronic perineal and pelvic pain. Arch Esp Urol. 2014;67(6):565–71.
17. Breivik H, Borchgrevink PC, Allen SM, Rosseland LA, Romundstad L, Hals EK, et al. Assessment of pain. Br J Anaesth. 2008;101(1):17–24.
18. Ramsay MA, Savage TM, Simpson BR, Goodwin R. Controlled sedation with alphaxalone-alphadolone. Br Med J. 1974;2(5920):656–9.
19. Tsai SJ, Lew HL, Date E, Bih Li. Treatment of detrusor-sphincter dyssynergia by pudendal nerve block in patients with spinal cord injury. Arch Phys Med Rehabil. 2002;83(5):714–7.
20. Ko HY, Kim KT. Treatment of external urethral sphincter hypertonicity by pudendal nerve block using phenol solution in patients with spinal cord injury. Spinal Cord. 1997;35(10):690–3.
21. Iremashvili W, Chepurkov AK, Kobaladze KM, Gamidov SI. Periprostatic local anesthesia with pudendal block for transperineal ultrasound-guided biopsies. J Urol. 2007;177(2):486–90.
22. Schnabel A, Reichl SU, Meyer-Frießem C, Zahn PK, Pogatzki-Zahn E. Periprostatic local anesthesia with pudendal block using phenol solution in patients with spinal cord injury. Br J Anaesth. 2006;96(3):377–80.
23. Kizilbash A, Ngô-Minh CT. Review of extended-release formulations of tramadol for postoperative pain treatment in children. Cochrane Database Syst Rev. 2015;3:CD009574.